# Krishna Institute of Medical Sciences (KIMS) — Stock analysis > Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/kims ## Current market snapshot - Exchange: NSE - Country: India - Price: ₹728 - Change: -0.42% - As of: 2026-11-06 - 1D return: -0.42% - 5D return: +3.73% - 1M return: +5.94% - Latest complete quarter: fy27_q2 ## Faxioms Analysis _As of 2026-11-06_ ### Technical Outlook As of 2026-11-06, KIMS trades at ₹728.00, positioned near the upper end of its 20-day range (+79.5%) but roughly mid-range over the last year (+53.9%). The daily trend is established and bullish, with price holding above the 20-period EMA and SMA while remaining below the 50-period and 200-period moving averages. ADX stands at 26.26, indicating defined directional movement, though the monthly trend remains weak (ADX 13.93). Recent activity shows a high-participation downward anomaly on 2026-11-06 (-0.4% return) and an active monthly 'Inside Bar' pattern, suggesting consolidation. Immediate resistance lies at ₹733.10 (pivot), followed by highs at ₹743.70 and ₹754.19. Support is found at ₹720.45, with deeper levels at ₹709.85 and ₹697.20. The stock carries an annualized volatility of +31.9% and a current drawdown of -14.4%. A break above ₹733.10 could signal renewed upside momentum, while a close below ₹720.45 may invalidate the short-term bullish structure. - Daily trend is bullish (price above 20/50 SMA, Supertrend up) but constrained by longer-term moving averages; ADX 26.26 confirms established direction. - Price is near 20-day range highs (+79.5%) with immediate resistance at ₹733.10; support sits at ₹720.45. - Monthly setup shows weakness (ADX 13.93) with an active 'Inside Bar' formation, indicating potential for breakout or breakdown. - Volatility is elevated at +31.9%; recent high-participation downward move on 2026-11-06 warrants monitoring. - Inside Bar - Bearish Engulfing Reversal - Morning Star - Bullish Engulfing Reversal - Doji - Shooting Star ### News Context Krishna Institute of Medical Sciences (KIMS) reported strong top-line growth for the second quarter, with revenue jumping 40% to ₹1,344 crore and consolidated net profit rising 12% to ₹75 crore. Despite this volume expansion, the company’s EBITDA margin narrowed to 19.4%, indicating that cost structures or pricing pressures offset some of the revenue gains. To support future scale, KIMS doubled the capacity of its Saveera Hospital in Anantapur, Andhra Pradesh, from 250 to 500 beds, adding specialized oncology and mother-and-child care infrastructure. Corporate governance was also reinforced through the board’s approval to merge KIMS Hospitals Private Limited with the parent entity and the reappointment of key leadership on five-year terms. On the analyst front, Prabhudas Lilladher issued a 'Buy' recommendation with a target price of ₹800 as of November 6, 2026. - Q2 Financials: Revenue surged 40% to ₹1,344 crore and net profit rose 12% to ₹75 crore, though EBITDA margin contracted to 19.4%. - Capacity Expansion: Saveera Hospital in Anantapur doubled bed capacity to 500, launching new Oncology and Mother & Child blocks. - Corporate Actions: Board approved the merger of KIMS Hospitals Private Limited with the parent and reappointed leadership for five-year terms. - Analyst View: Prabhudas Lilladher assigned a 'Buy' rating with a ₹800 target price on November 6, 2026. - [Buy Krishna Institute of Medical Sciences; target of Rs 800: Prabhudas Lilladher](https://www.moneycontrol.com/news/business/stocks/buy-krishna-institute-of-medical-sciences-target-of-rs-800-prabhudas-lilladher-2-14072846.html) - [KIMS Q2 net profit rises 12% to ₹75 crore, revenue jumps 40% but margin declines](https://www.cnbctv18.com/market/earnings/kims-q2-net-profit-rises-12pc-to-rs75-crore-revenue-jumps-40pc-but-margin-declines-20027292.htm) - [KIMS doubles Saveera Hospital capacity in Anantapur, Andhra Pradesh, to 500 beds](https://www.cnbctv18.com/market/stocks/kims-share-price-doubles-saveera-hospital-capacity-in-anantapur-andhra-pradesh-to-500-beds-20024312.htm) ### What Changed Krishna Institute of Medical Sciences (KIMS) disclosed the audio recording of its Analyst/Investor Meet for FY 26-27 on November 5, 2026. The call concluded at 11:00:00 IST, with the recording uploaded to the company website later that day. This filing is a routine procedural disclosure and reports no substantive business decisions or operational outcomes from the meeting itself. Separately, on the same date, Prabhudas Lilladher issued a 'Buy' recommendation for KIMS shares, setting a target price of ₹800. While this provides an external valuation perspective, it represents analyst opinion rather than a corporate action or financial result reported by the company. - On November 5, 2026, KIMS filed the audio recording of its FY 26-27 Analyst/Investor Meet with the NSE; the call ended at 11:00:00, but the filing notes no substantive business decisions were made. - Prabhudas Lilladher issued a 'Buy' recommendation with a target price of ₹800 on November 5, 2026, reflecting external brokerage sentiment rather than internal corporate developments. - [Buy Krishna Institute of Medical Sciences; target of Rs 800: Prabhudas Lilladher](https://www.moneycontrol.com/news/business/stocks/buy-krishna-institute-of-medical-sciences-target-of-rs-800-prabhudas-lilladher-2-14072846.html) - [Krishna Institute of Medical Sciences Limited has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_19312_WebXMLFile_20261105_200747888.xml) - [Krishna Institute of Medical Sciences Limited has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_19312_WebXMLFile_20261105_201504385.xml) - [Krishna Institute of Medical Sciences Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/KIMS_05112026201633_call_link.pdf) ### Official Filings Krishna Institute of Medical Sciences Limited (KIMS) reported unaudited consolidated financial results for Q2 FY27 (ended September 30, 2026), alongside a board-approved corporate restructuring. Financially, the company posted total income of ₹1,363 crore, with an EBITDA of ₹278.9 crore and PAT of ₹76 crore. An accompanying investor presentation detailed Group Operating Revenue at ₹1,344.4 million for Q2, marking a 39.9% quarter-on-quarter increase, supported by EBITDA margins of 18.7% and PAT of ₹1,025 million. Operational activity expanded significantly, with In-Patient (IP) volumes rising 12.7% to 122,000 and Out-Patient (OP) volumes growing 11.0% to 1,390,000. The Board also approved the amalgamation of its wholly-owned subsidiary, KIMS Hospitals Private Limited, into the holding company to simplify structure and achieve operational efficiencies; this related-party transaction is exempt from shareholder approval. Strategic expansion continues with the addition of a third hospital in Palakkad, Kerala, and a pipeline of 700+ beds through greenfield and acquisition opportunities across Telangana, Andhra Pradesh, Maharashtra, Karnataka, and Kerala. - Q2 FY27 Financials: Reported total income of ₹1,363 crore, EBITDA of ₹278.9 crore, and PAT of ₹76 crore; investor presentation cites Group Operating Revenue of ₹1,344.4 million (+39.9% QoQ) with 18.7% EBITDA margin. - Operational Growth: IP volumes increased 12.7% QoQ to 122,000, while OP volumes grew 11.0% QoQ to 1,390,000. - Corporate Restructuring: Board approved the merger of wholly-owned subsidiary KIMS Hospitals Private Limited into the holding company to eliminate multiple legal entities; no cash consideration or new shares issued. - Expansion Strategy: Added third hospital in Palakkad, Kerala; targeting 700+ additional beds via greenfield, acquisitions, and O&M opportunities across five states. - [Krishna Institute of Medical Sciences Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/KIMS_05112026110331_newspaperpublicationfinal.pdf) - [Krishna Institute of Medical Sciences Limited has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_19312_WebXMLFile_20261105_200747888.xml) - [Krishna Institute of Medical Sciences Limited has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_19312_WebXMLFile_20261105_201504385.xml) - [Krishna Institute of Medical Sciences Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/KIMS_05112026201633_call_link.pdf) - [Krishna Institute of Medical Sciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/KIMS_04112026184239_Outcome-final.pdf) - [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1753104_04112026074545_WEB.xml) - [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1753101_04112026074514_WEB.xml) - [Krishna Institute of Medical Sciences Limited has informed the Exchange regarding a press release dated November 04, 2026, titled "Press Release Q2FY27". |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/KIMS_04112026195613_Press_Release-final.pdf) - [Krishna Institute of Medical Sciences Limited has informed the Exchange about Investor Presentation |SUBJECT: Investor Presentation](https://nsearchives.nseindia.com/corporate/KIMS_04112026200444_Investorpresentationfinal.pdf) - [Krishna Institute of Medical Sciences Limited has informed the Exchange about Amalgamation/Merger |SUBJECT: Amalgamation/Merger](https://nsearchives.nseindia.com/corporate/KIMS_04112026203114_Disclosure_to_SE_Rajhmundry.pdf) ### Fundamentals Krishna Institute of Medical Sciences (KIMS) is executing a high-growth expansion phase, evidenced by robust revenue momentum offsetting near-term earnings compression. For Q2 FY2026-27, revenue from operations rose sequentially to ₹1,344 crore, while net profit more than doubled to ₹74.6 crore compared to Q1’s ₹37.4 crore. This sequential improvement coincided with a reduction in finance costs from ₹83.4 crore to ₹65.5 crore, suggesting improved debt servicing efficiency or lower borrowing rates as the company scales. However, the broader annual trajectory reveals significant margin pressure. While sales grew 28% year-on-year to ₹3,905 crore in FY2026, net profit fell sharply to ₹242 crore from ₹415 crore in FY2025. Interest expenses nearly doubled to ₹215 crore, and depreciation surged to ₹66 crore in the Sep 2025 quarter alone, reflecting the heavy capital expenditure cycle. The balance sheet confirms this aggressive build-out: fixed assets jumped to ₹5,710 crore, borrowings increased to ₹4,253 crore, and working capital days deteriorated to 52 days. Cash conversion quality has also weakened, with CFO/EBITDA dropping from 102% in Mar 2024 to 81% in Mar 2026. Despite these headwinds, return on capital employed remains positive at 10%, though down from 17% three years ago. - Q2 FY2026-27 Net Profit surged to ₹74.6 crore (up from ₹37.4 crore in Q1), driven by higher revenues and reduced finance costs (₹65.5 crore vs ₹83.4 crore). - FY2026 Annual Net Profit contracted to ₹242 crore from ₹415 crore in FY2025, despite 28% sales growth, due to surging interest (₹215 crore) and depreciation costs. - Borrowings rose to ₹4,253 crore and Fixed Assets expanded to ₹5,710 crore, indicating active capacity addition; however, ROCE declined to 10% from 17% in Mar 2024. - Cash flow conversion weakened significantly, with CFO/EBITDA falling to 81% in Mar 2026 from 102% in Mar 2024, signaling tighter cash generation relative to operating profits. ### Bull Case Krishna Institute of Medical Sciences (KIMS) presents a conditional upside case anchored by robust operational expansion and strong top-line growth, despite near-term margin compression. The company doubled the capacity of its KIMS Saveera Hospital in Anantapur to 500 beds, adding specialized oncology and mother-and-child blocks, which signals aggressive geographic and service-line penetration. Financially, Q2 revenue surged 40% year-on-year to ₹1,344 crore, with net profit rising 12% to ₹75 crore. While EBITDA margins narrowed to 19.4%, likely due to the ramp-up costs associated with new infrastructure, the substantial revenue jump indicates successful demand absorption. Corporate governance stability is reinforced by the board’s approval of the merger with KIMS Hospitals Private Limited and the reappointment of key leadership for five-year terms. Technically, the stock trades at ₹728.0 on the NSE, sitting just below immediate resistance levels, while maintaining a bullish monthly supertrend direction. This constructive setup suggests that if the company can stabilize or expand margins as the new capacities come online, the current valuation may reflect a temporary dislocation rather than fundamental weakness. - Operational Expansion: KIMS Saveera Hospital bed capacity doubled from 250 to 500 beds, including new oncology and neonatal intensive care units, signaling significant asset base growth. - Revenue Momentum: Q2 consolidated revenue jumped 40% to ₹1,344 crore, demonstrating strong top-line traction even as EBITDA margins contracted to 19.4%. - Governance Stability: The board approved the merger with KIMS Hospitals Private Limited and reappointed key leadership for five-year terms, reducing management transition risk. - Technical Structure: The stock closes at ₹728.0 with a bullish monthly supertrend direction, though it faces immediate resistance at ₹733.1 (0.70% above). - Margin Monitoring: Investors should monitor whether the 12% net profit growth (₹75 crore) accelerates relative to revenue as the new hospital facilities reach full utilization. - [Buy Krishna Institute of Medical Sciences; target of Rs 800: Prabhudas Lilladher](https://www.moneycontrol.com/news/business/stocks/buy-krishna-institute-of-medical-sciences-target-of-rs-800-prabhudas-lilladher-2-14072846.html) - [KIMS Q2 net profit rises 12% to ₹75 crore, revenue jumps 40% but margin declines](https://www.cnbctv18.com/market/earnings/kims-q2-net-profit-rises-12pc-to-rs75-crore-revenue-jumps-40pc-but-margin-declines-20027292.htm) - [KIMS doubles Saveera Hospital capacity in Anantapur, Andhra Pradesh, to 500 beds](https://www.cnbctv18.com/market/stocks/kims-share-price-doubles-saveera-hospital-capacity-in-anantapur-andhra-pradesh-to-500-beds-20024312.htm) - [Krishna Institute of Medical Sciences Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/KIMS_05112026110331_newspaperpublicationfinal.pdf) - [Krishna Institute of Medical Sciences Limited has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_19312_WebXMLFile_20261105_200747888.xml) - [Krishna Institute of Medical Sciences Limited has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_19312_WebXMLFile_20261105_201504385.xml) - [Krishna Institute of Medical Sciences Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/KIMS_05112026201633_call_link.pdf) - [Krishna Institute of Medical Sciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/KIMS_04112026184239_Outcome-final.pdf) - [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1753104_04112026074545_WEB.xml) - [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1753101_04112026074514_WEB.xml) ### Bear Case Krishna Institute of Medical Sciences (KIMS) faces a divergence between strong top-line growth and deteriorating profitability, alongside technical weakness in the stock. While Q2 revenue surged 40% to ₹1,344 crore, the EBITDA margin narrowed to 19.4%, indicating that cost pressures or operational inefficiencies are outpacing sales expansion despite a 12% rise in net profit to ₹75 crore. Technically, the stock is trading at ₹728.00 with a significant current drawdown of -14.4% from recent peaks, having experienced a maximum drawdown of -26.3%. The weekly trend is bearish, and the stock has declined 10.0% over the last three months, contrasting with an 18.2% year-to-date gain. High annualized volatility of 31.9% suggests elevated price risk for investors. - Margin Contraction: Q2 EBITDA margin narrowed to 19.4% despite a 40% revenue jump to ₹1,344 crore, signaling potential operational leverage issues. - Technical Weakness: The stock exhibits a bearish weekly trend and a current drawdown of -14.4%, with high annualized volatility of 31.9%. - Short-Term Decline: Shares have fallen 10.0% over the past three months, underperforming the 18.2% YTD return. - Resistance Proximity: Immediate resistance lies just 0.70% above the current price at ₹733.10, limiting near-term upside momentum. - [Buy Krishna Institute of Medical Sciences; target of Rs 800: Prabhudas Lilladher](https://www.moneycontrol.com/news/business/stocks/buy-krishna-institute-of-medical-sciences-target-of-rs-800-prabhudas-lilladher-2-14072846.html) - [KIMS Q2 net profit rises 12% to ₹75 crore, revenue jumps 40% but margin declines](https://www.cnbctv18.com/market/earnings/kims-q2-net-profit-rises-12pc-to-rs75-crore-revenue-jumps-40pc-but-margin-declines-20027292.htm) - [KIMS doubles Saveera Hospital capacity in Anantapur, Andhra Pradesh, to 500 beds](https://www.cnbctv18.com/market/stocks/kims-share-price-doubles-saveera-hospital-capacity-in-anantapur-andhra-pradesh-to-500-beds-20024312.htm) - [Krishna Institute of Medical Sciences Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/KIMS_05112026110331_newspaperpublicationfinal.pdf) - [Krishna Institute of Medical Sciences Limited has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_19312_WebXMLFile_20261105_200747888.xml) - [Krishna Institute of Medical Sciences Limited has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_19312_WebXMLFile_20261105_201504385.xml) - [Krishna Institute of Medical Sciences Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/KIMS_05112026201633_call_link.pdf) - [Krishna Institute of Medical Sciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/KIMS_04112026184239_Outcome-final.pdf) - [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1753104_04112026074545_WEB.xml) - [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1753101_04112026074514_WEB.xml) ### FAQs **What were Krishna Institute of Medical Sciences' key financial results for the quarter ended September 30, 2026?** For Q2 FY27 (ended September 30, 2026), KIMS reported consolidated net profit of ₹75 crore, a 12% increase year-on-year. Revenue jumped 40% to ₹1,344 crore. However, EBITDA margin narrowed to 19.4%. The Board also approved the merger of KIMS Hospitals Private Limited with the parent company. **How has KIMS expanded its operational capacity recently?** KIMS doubled the bed capacity of its Saveera Hospital in Anantapur, Andhra Pradesh, from 250 to 500 beds. This expansion, led by subsidiary Saveera Institute of Medical Sciences Private Limited, includes a new Oncology Block and a dedicated Mother and Child Block with neonatal intensive care services. **What is the current market price and technical outlook for KIMS stock?** As of November 6, 2026, KIMS closed at ₹728.0 on the NSE. The daily Supertrend is bullish, with resistance near ₹733.1 and support at ₹720.45. The stock has gained +18.2% year-to-date but is currently in a -14.4% drawdown from its peak. Annualized volatility stands at +31.9%. - [Buy Krishna Institute of Medical Sciences; target of Rs 800: Prabhudas Lilladher](https://www.moneycontrol.com/news/business/stocks/buy-krishna-institute-of-medical-sciences-target-of-rs-800-prabhudas-lilladher-2-14072846.html) - [KIMS Q2 net profit rises 12% to ₹75 crore, revenue jumps 40% but margin declines](https://www.cnbctv18.com/market/earnings/kims-q2-net-profit-rises-12pc-to-rs75-crore-revenue-jumps-40pc-but-margin-declines-20027292.htm) - [KIMS doubles Saveera Hospital capacity in Anantapur, Andhra Pradesh, to 500 beds](https://www.cnbctv18.com/market/stocks/kims-share-price-doubles-saveera-hospital-capacity-in-anantapur-andhra-pradesh-to-500-beds-20024312.htm) - [Krishna Institute of Medical Sciences Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/KIMS_05112026110331_newspaperpublicationfinal.pdf) - [Krishna Institute of Medical Sciences Limited has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_19312_WebXMLFile_20261105_200747888.xml) - [Krishna Institute of Medical Sciences Limited has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_19312_WebXMLFile_20261105_201504385.xml) - [Krishna Institute of Medical Sciences Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/KIMS_05112026201633_call_link.pdf) - [Krishna Institute of Medical Sciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/KIMS_04112026184239_Outcome-final.pdf) - [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1753104_04112026074545_WEB.xml) - [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1753101_04112026074514_WEB.xml) ## Technical analytics - As of: 2026-11-06 - Daily trend: Weak Uptrend - Weekly trend: Weak Downtrend - Pivot point: ₹733.1 - Risk regime: Price Risk Currently Contained ### Support levels - 623.496875 - 609.4496093749999 - 599.85 ### Resistance levels - 754.19375 - 775.3 - 783.9605468750001 ### Return and range metrics | Metric | Value | | --- | --- | | return_1 | -0.42% | | return_10 | +9.45% | | return_1m | +4.99% | | return_1y | +1.07% | | return_20 | +5.94% | | return_3m | -9.97% | | return_5 | +3.73% | | return_6m | +3.96% | | return_since_start | +20.66% | | return_ytd | +18.16% | ### Risk and volatility metrics | Metric | Value | | --- | --- | | state | contained_risk | | label | Price risk currently contained | | summary | Recent drawdown and price variability remain within the producer's contained-risk thresholds. | | maximum_drawdown | -26.26% | | annualized_volatility | +31.86% | ## Quarterly financials - Latest complete quarter: fy27_q2 # Krishna Institute of Medical Sciences Limited Q2 FY2026-27: Revenue up 14% sequentially Revenue from operations rose 14% quarter on quarter to ₹1,344.4 crore in Q2 FY2026-27, while profit before exceptional items and tax increased 67% to ₹92.7 crore. Reported profit before tax was ₹105.9 crore, including a ₹13.2 crore exceptional gain; profit for the period was ₹74.6 crore and basic EPS was ₹1.79. Operating cash flow of ₹443.1 crore was below investing outflows of ₹1,125 crore, resulting in negative free cash flow of ₹681.9 crore. At 30 September 2026, property, plant and equipment, equity and noncurrent borrowings were higher than at 31 March 2026. ## Revenue growth outpaced the sequential increase in expenses Revenue from operations increased from ₹1,179.5 crore in Q1 FY2026-27 to ₹1,344.4 crore in Q2, and was 40% higher than the ₹960.7 crore reported in Q2 FY2025-26. Total income rose to ₹1,363 crore from ₹1,195.9 crore in Q1; other income was ₹18.6 crore in Q2. Expenses increased 11.4% sequentially to ₹1,270.3 crore from ₹1,140.3 crore. Profit before exceptional items and tax consequently rose to ₹92.7 crore from ₹55.6 crore in Q1, but was 4.5% below the ₹97.1 crore reported in Q2 FY2025-26. ## Exceptional gain lifted reported profit before tax Finance costs declined 21% sequentially to ₹65.5 crore from ₹83.4 crore in Q1 FY2026-27, but were higher than the ₹45 crore recorded in Q2 FY2025-26. The ₹13.2 crore exceptional gain took profit before tax to ₹105.9 crore, compared with ₹55.6 crore in Q1 and ₹96.8 crore a year earlier. Tax expense was ₹30.9 crore, comprising current tax of ₹36 crore and a deferred tax credit of ₹5.1 crore. Profit for the period was ₹74.6 crore, versus ₹37.4 crore in Q1 FY2026-27 and ₹72 crore in Q2 FY2025-26. Basic EPS was ₹1.79, compared with ₹1.04 and ₹1.67, respectively. ## Investing outflows exceeded operating cash generation Cash flow from operating activities was ₹443.1 crore, while investing activities used ₹1,125 crore. Free cash flow was negative ₹681.9 crore, and financing activities provided ₹679.3 crore. Cash and cash equivalents stood at ₹52.8 crore on 30 September 2026, down from ₹55.4 crore on 31 March 2026. ## Asset base, equity and borrowings increased Property, plant and equipment stood at ₹4,797.7 crore on 30 September 2026, compared with ₹4,186.2 crore on 31 March 2026. Capital work in progress was ₹517.8 crore at quarter-end. Other intangible assets were ₹1,187.9 crore, compared with ₹801.7 crore at 30 June 2026 and ₹57 crore at 31 March 2026. Equity attributable to owners of the parent increased to ₹3,931.8 crore from ₹2,247.4 crore on 31 March 2026. Noncurrent borrowings rose to ₹2,914 crore from ₹2,672.6 crore over the same period. ## Key Takeaway Q2 delivered a substantial sequential improvement in revenue and pre-exceptional profit, while pre-exceptional profit remained slightly below its year-earlier level. The exceptional gain lifted reported pre-tax earnings, but operating cash generation did not cover investing outflows; the quarter also ended with higher property, plant and equipment, equity and noncurrent borrowings than at the previous fiscal year-end. ### Ratios ## Shareholding pattern - Quarter: FY2027-Q1 - As of: 2026-06-30 - Promoter holding: +32.50% - FII holding: +14.75% - DII holding: +34.42% - Mutual fund holding: +28.52% - Retail holding: +3.89% - Promoter pledged: +0.00% ### Major reported shareholders - Bhaskara Rao Bollineni — +25.02% - Bluebridge Capital Private Limited — +5.76% (Bodies Corporate) - Sbi Small Cap Fund — +5.17% - Axis Mutual Fund Trustee Limited A/C Axis Mutual Fund A/C Axis Small Cap Fund — +4.50% - Hdfc Small Cap Fund — +3.98% - Bollineni Seenaiah Naidu — +3.93% - Kotak Small Cap Fund — +3.61% - Invesco India Flexi Cap Fun — +3.54% - Amansa Holdings Private Limited — +2.24% - Nippon Life India Trustee Ltd-A/C Nippon India Small Cap Fund — +1.95% ## Official filings - 2026-11-05 — Generic Announcement: Krishna Institute of Medical Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/KIMS_05112026110331_newspaperpublicationfinal.pdf) - 2026-11-05 — Generic Announcement: Krishna Institute of Medical Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_19312_WebXMLFile_20261105_200747888.xml) - 2026-11-05 — Generic Announcement: Krishna Institute of Medical Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_19312_WebXMLFile_20261105_201504385.xml) - 2026-11-05 — Generic Announcement: Krishna Institute of Medical Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/KIMS_05112026201633_call_link.pdf) - 2026-11-04 — Generic Announcement: Krishna Institute of Medical Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/KIMS_04112026184239_Outcome-final.pdf) - 2026-11-04 — Financial Results Filing: Krishna Institute of Medical Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1753104_04112026074545_WEB.xml) - 2026-11-04 — Financial Results Filing: Krishna Institute of Medical Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1753101_04112026074514_WEB.xml) - 2026-11-04 — Press Release: Krishna Institute of Medical Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/KIMS_04112026195613_Press_Release-final.pdf) - 2026-11-04 — Earnings Presentation: Krishna Institute of Medical Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/KIMS_04112026200444_Investorpresentationfinal.pdf) - 2026-11-04 — Generic Announcement: Krishna Institute of Medical Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/KIMS_04112026203114_Disclosure_to_SE_Rajhmundry.pdf) - 2026-11-04 — Generic Announcement: Krishna Institute of Medical Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/REG30_Restructuring_19312_WebXMLFile_20261104_203402426.xml) - 2026-11-04 — Generic Announcement: Krishna Institute of Medical Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/KIMS_04112026204232_QIPOfinal.pdf) - 2026-11-04 — Generic Announcement: Krishna Institute of Medical Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/KIMS_04112026204936_PREFREPORTFINAL.pdf) - 2026-11-04 — Generic Announcement: Krishna Institute of Medical Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/KIMS_04112026205633_Disclosure_to_Deviation_of_funds_-_QIP.pdf) - 2026-11-04 — Generic Announcement: Krishna Institute of Medical Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/KIMS_04112026205735_Disclosure_to_Deviation_of_funds_-_Pref.pdf) - 2026-11-01 — Generic Announcement: Krishna Institute of Medical Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/KIMS_01112026152901_disclosure_Signed.pdf) - 2026-10-29 — Generic Announcement: Krishna Institute of Medical Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_19312_WebXMLFile_20261029_185458991.xml) - 2026-10-29 — Generic Announcement: Krishna Institute of Medical Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_19312_WebXMLFile_20261029_185912348.xml) - 2026-10-29 — Generic Announcement: Krishna Institute of Medical Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/KIMS_29102026190152_Covering_Letter_merged.pdf) - 2026-10-29 — Generic Announcement: Krishna Institute of Medical Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/KIMS_29102026230354_Sarvittam.pdf) - 2026-10-29 — Generic Announcement: Krishna Institute of Medical Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/KIMS_29102026230516_sangli_New.pdf) - 2026-10-29 — Generic Announcement: Krishna Institute of Medical Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/REG30_Restructuring_19312_WebXMLFile_20261029_230900236.xml) - 2026-10-29 — Generic Announcement: Krishna Institute of Medical Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/REG30_Restructuring_19312_WebXMLFile_20261029_231018549.xml) - 2026-10-28 — Generic Announcement: Krishna Institute of Medical Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/KIMS_28102026204050_General_Update_signed.pdf) - 2026-10-26 — Generic Announcement: Krishna Institute of Medical Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_19312_WebXMLFile_20261026_155410333.xml) ## News and market events - 2026-11-07 — MONEYCONTROL: **Buy Krishna Institute of Medical Sciences; target of Rs 885: ICICI Securities** — ICICI Securities has issued a 'Buy' recommendation for Krishna Institute of Medical Sciences, setting a price target of Rs 885. The note was published on November 7, 2026. — [Source](https://www.moneycontrol.com/news/business/earnings/buy-krishna-institute-of-medical-sciences-target-of-rs-885-icici-securities-14074308.html) - 2026-11-06 — MONEYCONTROL: **Buy Krishna Institute of Medical Sciences; target of Rs 800: Prabhudas Lilladher** — Prabhudas Lilladher has issued a 'Buy' recommendation for Krishna Institute of Medical Sciences, setting a target price of Rs 800. The article provides this specific investment advice from the brokerage firm regarding the listed entity. — [Source](https://www.moneycontrol.com/news/business/stocks/buy-krishna-institute-of-medical-sciences-target-of-rs-800-prabhudas-lilladher-2-14072846.html) - 2026-11-04 — CNBC-TV18: **KIMS Q2 net profit rises 12% to ₹75 crore, revenue jumps 40% but margin declines** — Krishna Institute of Medical Sciences reported a 12% rise in Q2 consolidated net profit to ₹75 crore and a 40% increase in revenue to ₹1,344 crore, although its EBITDA margin narrowed to 19.4%. The board also approved the merger of KIMS Hospitals Private Limited with the parent company and reappointed key leadership for five-year terms. — [Source](https://www.cnbctv18.com/market/earnings/kims-q2-net-profit-rises-12pc-to-rs75-crore-revenue-jumps-40pc-but-margin-declines-20027292.htm) - 2026-11-01 — CNBC-TV18: **KIMS doubles Saveera Hospital capacity in Anantapur, Andhra Pradesh, to 500 beds** — Krishna Institute of Medical Sciences Ltd has doubled the bed capacity of its KIMS Saveera Hospital in Anantapur, Andhra Pradesh, from 250 to 500 beds through an expansion led by its subsidiary, Saveera Institute of Medical Sciences Private Limited. The newly inaugurated facilities include an Oncology Block with advanced diagnostic infrastructure and a dedicated Mother and Child Block with neonatal intensive care services. — [Source](https://www.cnbctv18.com/market/stocks/kims-share-price-doubles-saveera-hospital-capacity-in-anantapur-andhra-pradesh-to-500-beds-20024312.htm) - 2026-10-05 — MONEYCONTROL: **Healthcare, pharma shares extend decline for 3rd day; Sun Pharma, Dr. Reddy's among top losers** — stock — [Source](https://www.moneycontrol.com/news/business/markets/healthcare-shares-extend-decline-for-3rd-day-sun-pharma-dr-reddy-s-fall-up-to-1-14044964.html) - 2026-10-01 — Economic Times: **Fortis, Apollo, other hospital stocks slump up to 10% in 2 days after SC questions steep markups. Buying opportunity?** — Hospital stocks extended losses for a second session after the Supreme Court questioned steep markups on cancer drugs and raised concerns over hospitals requiring patients to buy medicines from their own or designated pharmacies. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/fortis-apollo-other-hospital-stocks-slump-up-to-10-in-2-days-after-sc-questions-steep-markups-buying-opportunity/articleshow/134608717.cms) - 2026-10-01 — MONEYCONTROL: **Hospital stocks extend losses as drug-pricing regulation concerns linger; Apollo, Max among top Nifty losers** — hospital stocks today, healthcare stocks update, nifty healthcare update, apollo hospitals shares fall, max healthcare shares crash — [Source](https://www.moneycontrol.com/news/business/markets/hospital-stocks-extend-losses-as-drug-pricing-regulation-concerns-linger-apollo-max-among-top-nifty-losers-14042456.html) - 2026-10-01 — CNBC-TV18: **Hospital stocks sell-off a buying opportunity or a risk? Here is what analysts advice** — The Supreme Court, on Tuesday, September 29, flagged how drugs cost 2,700 to a retailer and are billed at 27,000 to patients in hospitals. The top court questioned where the 10x markup on prices was going. — [Source](https://www.cnbctv18.com/market/hospital-stocks-apollo-max-fortis-aster-share-price-fall-a-buying-chance-or-risk-supreme-court-price-cap-impact-20002607.htm) - 2026-09-30 — CNBC-TV18: **Explained - Why Hospital stocks Apollo, Max, Fortis, KIMS are down up to 6% on Wednesday** — A Public Interest Litigation was being heard by the Supreme Court on price fixation of drugs, mandates for generics. The government was also questioned by the Apex Court as to why there is no 16% mark up across all drugs and devices. — [Source](https://www.cnbctv18.com/market/why-hospital-stocks-apollo-max-fortis-global-share-price-are-falling-explained-drug-pricing-markup-supreme-court-observation-20001775.htm) - 2026-09-30 — BUSINESSTODAY: **Yatharth, Apollo, KIMS, Fortis, Max Healthcare stocks fall: Why hospital stocks are declining today** — Yatharth Hospital, Apollo Hospitals, KIMS, Fortis Healthcare, Max Healthcare, hospital stocks, healthcare stocks, Supreme Court, cancer medicine markup, medicine pricing, corporate hospitals, hospital shares, healthcare sector, hospital stocks today — [Source](https://www.businesstoday.in/markets/stocks/story/yatharth-apollo-kims-fortis-max-healthcare-stocks-fall-why-hospital-stocks-are-declining-today-558704-2026-09-30) - 2026-09-30 — MONEYCONTROL: **Apollo Hospitals, Yatharth, others fall up to 6% on SC's 'corporate hospitals don't spare anyone' remark** — Apollo Hospitals, Yatharth, Supreme Court, Max Healthcare — [Source](https://www.moneycontrol.com/news/business/markets/apollo-hospitals-yatharth-others-fall-up-to-6-on-sc-s-corporate-hospitals-don-t-spare-anyone-remark-14041699.html) - 2026-09-10 — CNBC-TV18: **KIMS enters O&M agreement to manage 183-bed Trust Hospital in Kakinada, Andhra Pradesh** — Shares of Krishna Institute of Medical Sciences Ltd ended at ₹774.00, up by ₹1.20, or 9.20%, on the BSE. — [Source](https://www.cnbctv18.com/market/stocks/kims-share-price-enters-om-agreement-to-manage-183-bed-trust-hospital-in-kakinada-andhra-pradesh-19988692.htm) - 2026-08-21 — BUSINESSTODAY: **Top stocks in news: IndiGo, HAL, Amagi Labs, TMPV, Manipal Health, RailTel Corp, KIMS, Niva Bupa** — Top stocks in news: IndiGo, HAL, Amagi Labs, TMPV, Manipal Health, RailTel Corp, KIMS, Niva Bupa — [Source](https://www.businesstoday.in/markets/stocks/story/top-stocks-in-news-indigo-hal-amagi-labs-tmpv-manipal-health-railtel-corp-kims-niva-bupa-550478-2026-08-21) - 2026-08-21 — Mint: **Stocks to watch: HAL, RailTel, Tata Motors PV among shares in focus today; check list here** — Stock market today: On Thursday, the Nifty 50 ended the session 0.55% higher at 24,211, meanwhile, Sensex gained 0.75% to settle at 77,488. — [Source](https://www.livemint.com/market/stock-market-news/stocks-to-watch-hal-railtel-tata-motors-pv-among-shares-in-focus-today-check-list-here-11787243365674.html) - 2026-08-21 — MONEYCONTROL: **Stocks to Watch Today: Amagi Media Labs, Manipal Health, Saatvik Green Energy, RailTel Corp, Kfin Technologies, Krishna Institute of Medical Sciences in focus on 21 August** — Stocks to watch, stocks in focus today, stocks in focus, share market today, top stocks, shares in focus today, shares today, today stocks to watch, trending stocks, trending stocks today, markets today, buzzing stocks, stocks today, stock market today,Manipal Health Enterprises,Amagi Media Labs,Saatvik Green Energy,Torrent Power,Krishna Institute of Medical Sciences,RailTel Corporation of India,Lemon Tree Hotels,Rallis India,Kfin Technologies,Pfizer,Amrutanjan Health Care,Apollo Pipes,Welspun Investments and Commercials,Credent Connect N Care,Technocrats Plasma Systems, ENS Enterprises, Skytech Infinite Platform — [Source](https://www.moneycontrol.com/news/business/markets/stocks-to-watch-today-amagi-media-labs-manipal-health-saatvik-green-energy-railtel-corp-kfin-technologies-krishna-institute-of-medical-sciences-in-focus-on-21-august-14011891.html) - 2026-08-20 — CNBC-TV18: **Stocks to Watch for August 21: RailTel, KIMS, Saatvik Green Energy, Manipal Health and more** — From Manipal Health’s Q1 results and Saatvik Green Energy’s ₹190 crore solar module order to RailTel’s ₹164.79 crore Western Coalfields order, Tata Motors PV’s Sanand operations update and Niva Bupa’s IRDAI action, here are the stocks to watch ahead of Friday market session. — [Source](https://www.cnbctv18.com/photos/market/stocks-to-watch-for-august-21-railtel-hal-kims-manipal-health-share-price-19973747.htm) - 2026-08-20 — CNBC-TV18: **KIMS to operate 250-bed Arete Hospital in Hyderabad under 5-year O&M deal** — Shares of Krishna Institute of Medical Sciences Ltd ended at ₹788.00, down by ₹0.60, or 0.076%, on the BSE. — [Source](https://www.cnbctv18.com/market/stocks/kims-share-price-to-operate-250-bed-arete-hospital-in-hyderabad-under-5-year-om-deal-19973830.htm) - 2026-08-04 — BUSINESSTODAY: **Top stocks in news: Paytm, SBI Funds, LIC, Meesho, DLF, Kalpataru, IREDA, Arvind, KIMS** — Stocks in news, Stocks in buzz, Stocks to buy, Stocks to watch, Paytm, SBI Funds, LIC of India, Meesho, DLF, Kalpataru, IREDA, Arvind, KIMS, GE Shipping, DOMS Industries, One 97 Communications, SBI Funds Management, Life Insurance Corporation of India, Indian Renewable Energy Development Agency, KEI Industries, Krishna Institute of Medical Sciences, Torrent Power, Texmaco Rail and Engineering, Great Eastern Shipping Company, UPL, GlaxoSmithKline Pharmaceuticals, Kansai Nerolac Paints, Thomas Cook (India), Gulf Oil Lubricants, VVIP Infratech, Restaurant Brands Asia — [Source](https://www.businesstoday.in/markets/stocks/story/top-stocks-in-news-paytm-sbi-funds-lic-meesho-dlf-kalpataru-ireda-arvind-kims-546987-2026-08-04) - 2026-08-03 — CNBC-TV18: **KIMS Q1 profit falls 47% despite 35% revenue growth; bed capacity expands** — Krishna Institute of Medical Sciences reported strong revenue growth in the June quarter as new hospitals and higher patient volumes boosted operations, but profits declined due to margin pressure and other factors. — [Source](https://www.cnbctv18.com/market/earnings/kims-q1-profit-falls-47-despite-35-revenue-growth-bed-capacity-expands-19960785.htm) ## Business profile **Strategic vision:** Operates a network of multi-specialty hospitals in India. ### Business segments - **Healthcare Services:** The company provides comprehensive healthcare services across primary, secondary, and tertiary care. Its hospitals offer specialized treatments in cardiac sciences, neurosciences, oncology, orthopedics, renal sciences, and organ transplantation. ### Competitive strengths - Operates a network of multi-specialty hospitals. ## Related stocks - [Abbott India Limited (Healthcare)](https://faxioms.com/stocks/abbotindia) — -0.85% - [Acutaas Chemicals Limited (Healthcare)](https://faxioms.com/stocks/acutaas) — +0.30% - [Ajanta Pharma Limited (Healthcare)](https://faxioms.com/stocks/ajantpharm) — +0.55% - [Anthem Biosciences Limited (Healthcare)](https://faxioms.com/stocks/anthem) — +0.16% - [Biocon Limited (Healthcare)](https://faxioms.com/stocks/biocon) — +0.86% ## Freshness and sources - Data as of: 2026-11-06 - Source: Faxioms public stock analysis API Canonical: https://faxioms.com/stocks/kims Markdown representation: https://faxioms.com/stocks/kims?render=md